NeviMed

Company Overview

Snapshot

Founded in March 2015 by Uri Shkolnik, NeviMed operates with 1–10 employees. The company is currently in the Pre-Funding stage and ceased operations in May 2023.

Business overview

NeviMed develops the DermoScout, a full-body skin scanner designed for monitoring various abnormal skin conditions. This medical device integrates advanced algorithms to compare, track, screen, and diagnose multiple phenomena, with its first generation focusing on melanoma screening. The DermoScout aims to assist dermatologists in patient examinations, identify false signs or symptoms, and reduce examination time, thereby enhancing care quality for patients and improving time and revenue management for healthcare providers. The company operates within the Health Tech & Life Sciences sector, specifically targeting the medical devices and diagnostics devices markets.

Company Intelligence Q&A

What is NeviMed's primary product?

NeviMed's primary product is the DermoScout, a full-body skin scanner designed for monitoring abnormal skin conditions and assisting dermatologists with examinations.

When was NeviMed founded and by whom?

NeviMed was founded in March 2015 by Uri Shkolnik.

What is the current operational status of NeviMed?

NeviMed is currently non-active and ceased to operate in May 2023.

What is the core technology behind the DermoScout?

The DermoScout utilizes advanced algorithms for comparing, tracking, screening, and diagnosing various skin conditions, with an initial focus on melanoma screening.

Which market does NeviMed primarily target?

NeviMed primarily targets the healthcare market, specifically dermatologists and healthcare providers, with its diagnostic devices.